Biogen Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;'>BII</div>
BIIB -- USA Stock  

USD 274.48  6.18  2.30%

Biogen Net Income Per Employee is projected to increase significantly based on the last few years of reporting. The past year's Net Income Per Employee was at 795,743. The current year Enterprise Value is expected to grow to about 60.4 B, whereas Revenue Per Employee is forecasted to decline to about 1.6 M. Biogen Inc is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 22nd of July 2020. While some of us are getting worried about healthcare space, it is reasonable to go over Biogen Inc using its current fundamental data. We will analyze why Biogen investors may still consider a stake in the business. Will investors continue to hold, or should we expect a sell-off?
Published over two months ago
View all stories for Biogen | View All Stories
Should you pay attention to changing Biogen fundamentals?
Biogen is FAIRLY VALUED at 283.81 per share with modest projections ahead. Biogen Inc secures Sharpe Ratio (or Efficiency) of -0.0373, which signifies that the company had -0.0373% of return per unit of risk over the last month. Macroaxis standpoint towards foreseeing the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Biogen Inc exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Biogen Inc mean deviation of 1.71, and risk adjusted performance of (0.14) to double-check the risk estimate we provide.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Biogen income statement, its balance sheet, and the statement of cash flows. Potential Biogen investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Biogen investors may use each financial statement separately, they are all related. The changes in Biogen's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Biogen's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Biogen fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Biogen performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Biogen shares is the value that is considered the true value of the share. If the intrinsic value Biogen is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Biogen. Please read more on our fundamental analysis page.

Are Biogen Earnings Expected to grow?

The future earnings power of Biogen involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Biogen factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Biogen stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Biogen expected earnings.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Biogen, but it might be worth checking our own buy vs. sell analysis

Biogen Gross Profit

Biogen Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Biogen previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Biogen Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Biogen exotic insider transaction detected

Legal trades by Biogen insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Biogen insider trading alert for general transaction of common stock by Mcdonnell Michael R, EVP Chief Financial Officer, on 20th of August 2020. This event was filed by Biogen Inc with SEC on 2020-08-20. Initial filing of beneficial ownership - SEC Form 3 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Biogen Investor Appetite?

Institutional investor usually refers to an organization that invests money in Biogen on behalf of clients or other money managers. Buying and selling of large positions of Biogen stock by institutional investors can create supply and demand imbalances that result in sudden price moves of Biogen stock. Let's take a look at how the ownership of Biogen is distributed among investors.

Ownership Allocation

Biogen Inc retains a total of 166.09 Million outstanding shares. The majority of Biogen Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biogen Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biogen. Please pay attention to any change in the institutional holdings of Biogen Inc as this could imply that something significant has changed or about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Retail Investors
6.19%
Institutions
93.15%
Retail Investors6.19
Insiders0.66
Institutions93.15

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biogen has an asset utilization ratio of 63.03 percent. This suggests that the company is making $0.63 for each dollar of assets. An increasing asset utilization means that Biogen Inc is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
7.5 B
Assets Non Current
16.4 B
Goodwill
8.2 B
Current Assets7.48 Billion21.41
Assets Non Current16.36 Billion46.82
Goodwill8.25 Billion23.61
Tax Assets2.86 Billion8.17

Will Biogen slip impact its fundamentals?

Current total risk alpha indicator falls down to -0.47. Possible price jump? Biogen Inc exhibits very low volatility with skewness of -1.03 and kurtosis of 3.31. However, we advise investors to further study Biogen Inc technical indicators to make sure all market info is available and is reliable.

Our Conclusion on Biogen

Whereas some companies in the drug manufacturers?general industry are either recovering or due for a correction, Biogen may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 21st of July 2020, our analysis shows that Biogen moves indifferently to market moves. The company is fairly valued and projects low probability of bankruptcy for the next 2 years. Our latest 30 days 'Buy-Sell' recommendation on the company is Cautious Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Biogen Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com